Jonathan Meyers is a prominent inventor based in Bloomington, IN (US), known for his significant contributions to the field of biochemistry and pharmaceuticals. He holds a total of 3 patents, focusing primarily on insulin analogs that exhibit high activity at the insulin receptor. His work has the potential to enhance diabetes treatment through innovative drug design.

Latest Patents

Meyers' latest patents include groundbreaking developments in single-chain insulin agonists. These insulin analogs are designed to have high potency and specificity for the insulin receptor. The patents disclose the use of optimally sized linking moieties to connect human insulin A and B chains, or their analogs and derivatives. One embodiment features a polyethylene glycol linking moiety consisting of 6-16 monomer units, while another includes a non-native amino acid sequence derived from the IGF-1 C-peptide, comprising between 8 to 12 amino acids. Additionally, the patents describe prodrug and conjugate derivatives of these single-chain insulin analogs, further expanding their therapeutic potential.

Career Highlights

Jonathan Meyers is affiliated with Indiana University, where he continues to advance research in insulin analogs and their applications. His innovative work has positioned him as a key figure in the development of new diabetes treatments.

Collaborations

Meyers has collaborated with notable colleagues in his field, including Richard Dennis DiMarchi and Todd Parody. These partnerships have fostered a collaborative environment that enhances the research and development of insulin therapies.

Conclusion

Jonathan Meyers' contributions to the field of insulin analogs represent a significant advancement in diabetes treatment. His innovative patents and collaborations highlight the importance of research in developing effective therapies for patients.

Profile summary based on public USPTO records.